Key result
A critical analysis of the COMPASS trial showed that younger patients derived greater benefit from the rivaroxaban plus aspirin combination relative to aspirin alone based on number needed to treat.
Why the study?
Does rivaroxaban alone or in combination with aspirin improve secondary prevention compared to aspirin alone in younger Indian patients with stable cardiovascular disease?
Does rivaroxaban alone or in combination with aspirin improve secondary prevention compared to aspirin alone in younger Indian patients with stable cardiovascular disease?
Answers are grounded in this paper and cite their sources.
A critical analysis of the COMPASS trial suggests that younger Indian patients with stable cardiovascular disease may derive greater benefit from the combination of rivaroxaban and aspirin for secondary prevention compared to older populations.
The recently published Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial evaluated the hypothesis that rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary prevention. In India, stable cardiovascular disease occurs in a much younger age group relative to the rest of the world. Our critical analysis of COMPASS trial showed that the younger age group appeared to derive greater benefit from the rivaroxaban+aspirin combination (relative to aspirin alone) as seen with number needed to treat metrics as compared to the older age group.
No takes yet. Share an insight, caveat, or question.
Kerkar et al. (2018) conducted a review in Stable cardiovascular disease. Rivaroxaban alone or in combination with aspirin vs. Aspirin alone was evaluated on Secondary prevention. A critical analysis of the COMPASS trial showed that younger patients derived greater benefit from the rivaroxaban plus aspirin combination relative to aspirin alone based on number needed to treat.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: